Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: A retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)

Jeffrey B. Washam, Susanna R. Stevens, Yuliya Lokhnygina, Jonathan L. Halperin, Günter Breithardt, Daniel E. Singer, Kenneth W. Mahaffey, Graeme J. Hankey, Scott D. Berkowitz, Christopher C. Nessel, Keith A.A. Fox, Robert M. Califf, Jonathan P. Piccini, Manesh R. Patel

Research output: Contribution to journalArticlepeer-review

118 Scopus citations

Fingerprint

Dive into the research topics of 'Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: A retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)'. Together they form a unique fingerprint.

Medicine & Life Sciences